A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study
Latest Information Update: 05 Jul 2026
At a glance
- Drugs Lunsekimig (Primary) ; Mometasone (Primary)
- Indications Rhinosinusitis
- Focus Adverse reactions
- Acronyms ENSEMBLE
- Sponsors Sanofi
Most Recent Events
- 02 Jul 2026 Planned number of patients changed from 67 to 74.
- 18 May 2025 Status changed from not yet recruiting to recruiting.
- 10 Apr 2025 New trial record